Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'

Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

The analyst comments "Sanofi (SNY)'s decision to stop the Phase 3 MOBILIZE study of riliprubart in SOC-refractory CIDP at the pre-specified interim has driven fair investor scrutiny to DNTH's CAPTIVATE program, but on balance we see today's news as constructive for... More

Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies

Jefferies analyst Maury Raycroft raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $132.00 (from $110.00) while maintaining a Buy rating.... More

TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'

TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "SNY stopping riliprubart's MOBILIZE on futility is molecule/trial-specific rather than thesisbreaking for DNTH. DNTH mgmt notes Ph3 CAPTIVATE for claseprubart (C1s) continues to... More

Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "Sanofi announced it is stopping its Phase 3 study evaluating riliprubart in refractory CIDP patients, a C1s inhibitor and direct competitor to claseprubart, due to an interim readout analysis... More

Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive'

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

The analyst comments "This morning, Sanofi stopped the MOBILIZE Ph3 study of riliprubart in CIDP (NCT06290128, in SOC-refractory patients) due to underwhelming efficacy at an interim analysis, with no new safety signals. DNTH stock traded to $65/sh from $85/ sh as a readthrough (23%). This appears to be a strong overreaction and we expect an eventual rebound. A few points of consideration: For long-term investors: Buyside had been previously hesitant whether potency & dosing would make a difference between Dianthus... More

Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'

Truist Securities analyst Danielle Brill reiterated a Buy rating and $110.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "This morning, DNTHs direct competitor Sanofi (SNY, NR) announced the discontinuation of one of its two pivotal CIDP trials evaluating riliprubart, its active C1s inhibitor. The discontinued study, MOBILIZE, was a placebo-controlled... More

Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel

Stifel analyst Alex Thompson reiterated a Buy rating and $120.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst commented, "Sanofi announced this morning that they are discontinuing the MOBILIZE Ph3 of Riliprubart in CIDP patients refractory to IVIg. This was... More